Back to Search
Start Over
A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction
- Source :
- Cardiovascular Drugs and Therapy, 20(2), 135-141. SPRINGER
- Publication Year :
- 2006
- Publisher :
- SPRINGER, 2006.
-
Abstract
- Aims: Besides stimulating hematopoiesis, erythropoietin (EPO) protects against experimental ischemic injury in the heart. The present study evaluated the safety and tolerability of EPO treatment in non-anemic patients with acute myocardial infarction (MI). Methods and Results: In this single-center, investigator-initiated, prospective study, patients with a first acute MI were randomized to one bolus of 300 μg darbepoetin alfa or no additional medication before primary coronary intervention. Twenty-two patients (mean age 59 ± 2 years) were included. In the darbepoetin group, serum EPO-levels increased to 130–270 times that of controls, within the first 24 h. After darbepoetin administration, only small and non-significant changes in hematocrit levels were observed, while endothelial progenitor cells (EPCs, CD34+/CD45−) were increased at 72 h (2.8 vs. 1.0 cells/μl in control group, p < 0.01). No adverse events were recorded during the 30-day follow-up. After 4 months, left ventricular ejection fraction was similar in the two groups (52 ± 3% in darbepoetin vs. 48 ± 5% in control group, p = NS). Conclusions: Intravenous single high-dose darbepoetin alfa in acute MI is both safe and well tolerated. Darbepoetin treatment after MI stimulates EPCs mobilization. The results of this first pilot study support a larger scale clinical trial to establish efficacy of EPO administration in patients after acute MI.
- Subjects :
- Male
HEMODIALYSIS
Reticulocytes
Darbepoetin alfa
Myocardial Infarction
Antigens, CD34
law.invention
Electrocardiography
Hemoglobins
Bolus (medicine)
Randomized controlled trial
law
Pharmacology (medical)
Myocardial infarction
Prospective Studies
Angioplasty, Balloon, Coronary
Ejection fraction
General Medicine
Middle Aged
CHRONIC HEART-FAILURE
Treatment Outcome
HEMOGLOBIN LEVELS
Tolerability
Injections, Intravenous
Cardiology
erythropoietin
Cardiology and Cardiovascular Medicine
medicine.drug
Blood Platelets
medicine.medical_specialty
acute myocardial infarction
RATS
Heart Conduction System
LEFT-VENTRICULAR FUNCTION
Internal medicine
medicine
Humans
ANEMIA
ENDOTHELIAL PROGENITOR CELLS
Pharmacology
business.industry
Patient Selection
MORTALITY
Epoetin alfa
Mesenchymal Stem Cells
RECOMBINANT-HUMAN-ERYTHROPOIETIN
medicine.disease
Surgery
Blood Cell Count
SIZE
Erythropoietin
Tachycardia, Ventricular
Feasibility Studies
Leukocyte Common Antigens
business
Subjects
Details
- Language :
- English
- ISSN :
- 09203206
- Volume :
- 20
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Cardiovascular Drugs and Therapy
- Accession number :
- edsair.doi.dedup.....063e9683fed339b7fbfd3212abffa552